Tempest Therapeutics, Inc. (TPST)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Stephen R. Brady J.D., LLM | CEO, President & Director | 894.3k | -- | 1970 |
| Mr. Nicholas Maestas | CFO, Head of Corporate Strategy & Secretary | 465.62k | -- | 1980 |
| Dr. Samuel Whiting M.D., Ph.D. | Executive VP, Chief Medical Officer and Head of R&D | 671.39k | -- | 1966 |
| Mr. Justin Trojanowski CPA | Corporate Controller, Treasurer & Principal Accounting Officer | -- | -- | 1988 |
| Ms. Lindsay Young | Head of Human Resources | -- | -- | -- |
Tempest Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 24
Description
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers. The company's two clinical programs Amezalpat formerly PST-1120, an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha, which is in Phase III; and TPST-1495, a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, which is in Phase II. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Corporate Governance
Upcoming Events
August 6, 2025 at 8:00 PM UTC - August 11, 2025 at 8:00 PM UTC
Tempest Therapeutics, Inc. Earnings Date
Recent Events
January 24, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission